… efficacy of molnupiravir in the treatment of COVID-19. Among 202 treated participants, virus
isolation was significantly lower in participants receiving 800 mg molnupiravir (… molnupiravir …

… the efficacy of 800 mg molnupiravir twice daily for five days given within five days of the onset
of mild or moderate covid-19 … An earlier trial (Move-In) of molnupiravir in hospital inpatients …

… We found full published results of phase 3, double-blind, randomized study (MOVe-OUT)
that was planned to assess efficacy and safety of molnupiravir in 1433 non-hospitalized adult (…

… with COVID-19, through … molnupiravir demonstrated significant efficacy versus placebo in
reducing hospitalization or death among unvaccinated adults with mild-to-moderate COVID-19 …

… Molnupiravir is an antiviral that has shown clinical efficacy against mild-to-moderate COVID-19
but … Our findings illustrated that molnupiravir was most effective at combatting COVID-19 …

… drugs indicated for COVID-19 such as molnupiravir, we must … the potential to reduce mortality
associated with COVID-19. … provided compelling evidence of the efficacy of molnupiravir …

… We here evaluated the efficacy of molnupiravir in patients with mild-to-moderate coronavirus
disease 2019 (COVID-19) during the Omicron variant surge in Fukushima Prefecture, Japan…

… , we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients
… Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against …

… On day 50 of the project, the sponsor submitted a phase 2/3 protocol to FDA for a study of
molnupiravir in patients with symptomatic COVID-19 not requiring hospitalization. FDA …

… COVID-19 [11, 12]. This review aimed to give an overview of recently discovered Merck’s
molnupiravir, demonstrating its safety and efficacy … new COVID protocol in a sequential manner. …